Pacific Biosciences Valuation
| PACB Stock | USD 1.80 0.03 1.69% |
Based on Macroaxis valuation methodology, the company appears to be overvalued. Pacific Biosciences holds a recent Real Value of $1.58 per share. The prevailing price of the company is $1.8. Our model determines the value of Pacific Biosciences from analyzing the company fundamentals such as Return On Equity of -0.65, operating margin of (1.40) %, and Shares Outstanding of 273.86 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Pacific Biosciences' valuation include:
Price Book 1.0396 | Enterprise Value 920.7 M | Enterprise Value Ebitda (4.15) | Price Sales 2.7996 | Enterprise Value Revenue 5.3172 |
Overvalued
Today
Please note that Pacific Biosciences' price fluctuation is extremely dangerous at this time. Calculation of the real value of Pacific Biosciences is based on 3 months time horizon. Increasing Pacific Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Pacific Biosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Pacific Stock. However, Pacific Biosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.8 | Real 1.58 | Target 13.77 | Hype 1.77 | Naive 1.3 |
The real value of Pacific Stock, also known as its intrinsic value, is the underlying worth of Pacific Biosciences Company, which is reflected in its stock price. It is based on Pacific Biosciences' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Pacific Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Pacific Biosciences of helps investors to forecast how Pacific stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Pacific Biosciences more accurately as focusing exclusively on Pacific Biosciences' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Pacific Biosciences' intrinsic value based on its ongoing forecasts of Pacific Biosciences' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Pacific Biosciences' closest peers. If more than one evaluation category is relevant for Pacific Biosciences we suggest using both methods to arrive at a better estimate.
Pacific Biosciences Cash |
|
Pacific Valuation Trend
Comparing Pacific Biosciences' enterprise value against its market capitalization is a good way to estimate the value of Pacific Biosciences of uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Pacific Biosciences Total Value Analysis
Pacific Biosciences of is at this time forecasted to have valuation of 920.65 M with market capitalization of 484.74 M, debt of 933.93 M, and cash on hands of 834.34 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Pacific Biosciences fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
920.65 M | 484.74 M | 933.93 M | 834.34 M |
Pacific Biosciences Investor Information
About 83.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.04. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Pacific Biosciences has Price/Earnings (P/E) ratio of 197.88. The entity recorded a loss per share of 1.46. The firm had not issued any dividends in recent years. Based on the key indicators related to Pacific Biosciences' liquidity, profitability, solvency, and operating efficiency, Pacific Biosciences of is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Pacific Biosciences Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Pacific Biosciences has an asset utilization ratio of 11.48 percent. This suggests that the Company is making $0.11 for each dollar of assets. An increasing asset utilization means that Pacific Biosciences of is more efficient with each dollar of assets it utilizes for everyday operations.Pacific Biosciences Ownership Allocation
Pacific Biosciences owns a total of 273.86 Million outstanding shares. The majority of Pacific Biosciences of outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Pacific Biosciences to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Pacific Biosciences. Please pay attention to any change in the institutional holdings of Pacific Biosciences as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Pacific Biosciences Profitability Analysis
The company reported the previous year's revenue of 200.52 M. Net Loss for the year was (306.74 M) with profit before overhead, payroll, taxes, and interest of 53.47 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Pacific Biosciences' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Pacific Biosciences and how it compares across the competition.
About Pacific Biosciences Valuation
The stock valuation mechanism determines Pacific Biosciences' current worth on a weekly basis. Our valuation model uses a comparative analysis of Pacific Biosciences. We calculate exposure to Pacific Biosciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Pacific Biosciences's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 52.8 M | 28.1 M | |
| Pretax Profit Margin | (1.59) | (1.67) | |
| Operating Profit Margin | (1.67) | (1.75) | |
| Net Loss | (1.53) | (1.61) | |
| Gross Profit Margin | 0.26 | 0.29 |
Pacific Biosciences Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 253.6 M |
Pacific Biosciences Current Valuation Indicators
Valuation refers to the process of determining the present value of Pacific Biosciences of and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Pacific we look at many different elements of the entity such as Pacific's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Pacific Biosciences, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Pacific Biosciences' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Pacific Biosciences' worth.Complementary Tools for Pacific Stock analysis
When running Pacific Biosciences' price analysis, check to measure Pacific Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacific Biosciences is operating at the current time. Most of Pacific Biosciences' value examination focuses on studying past and present price action to predict the probability of Pacific Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacific Biosciences' price. Additionally, you may evaluate how the addition of Pacific Biosciences to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Global Correlations Find global opportunities by holding instruments from different markets |